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Abstract 
Plasma membrane ion channels and mitochondrial electron transport complexes (mETC) 
are recognised “off-targets” for certain drugs. Simvastatin is one such drug, a lipophilic statin 
used to treat hypercholesterolaemia, but which is also associated with adverse effects like 
myopathy and increased risk of glucose intolerance. Such myopathy is thought to arise 
through adverse actions of simvastatin on skeletal muscle mETC and mitochondrial 
respiration. In this study we investigated whether the glucose intolerance associated with 
simvastatin is also mediated via adverse effects on mETC in pancreatic beta-cells since 
mitochondrial respiration underlies insulin secretion from these cells, an effect in part 
mediated by promotion of Ca2+ influx via opening of  voltage-gated Ca2+ channels (VGCCs). 
We used murine pancreatic beta-cells to investigate these ideas. Mitochondrial membrane 
potential, oxygen consumption and ATP-sensitive-K+-channel activity were monitored as 
markers of mETC activity,  respiration and cellular ATP/ADP ratio respectively; Ca2+ channel 
activity and Ca2+ influx were also measured. In intact beta-cells, simvastatin inhibited 
oxidative respiration (IC50 ~ 3 µM) and mETC (1< IC50 < 10 µM), effects expected to impair 
VGCC opening. Consistent with this idea simvastatin > 0.1 µM reversed activation of VGCCs 
by glucose but had no significant effect in the sugar’s absence. The VGCC effects were 
mimicked by rotenone which also decreased respiration and ATP/ADP. This study 
demonstrates modulation of beta-cell VGCC activity by mitochondrial respiration and their 
sensitivity to mETC inhibitors. This reveals a novel outcome for the action of drugs like 
simvastatin for which mETC is an “off target”. 
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Introduction 
Mitochondrial electron transport (mETC) complexes (Nadanaciva et al., 2007; Hargreaves 
et al., 2016; Wallace, 2008) and plasma membrane ion channels are well recognised “off 
targets” for drugs (Lynch et al., 2017; Real et al., 2018). For some drugs, both moieties may 
be “off targets”; a situation which confounds the interpretation of adverse drug effects both 
in the clinic and laboratory. An example of this occurs in insulin secreting beta cells with the 
3-hydroxy-3-methyl glutaryl coenzyme A (HMG-CoA) reductase inhibitor, simvastatin, a 
lipophilic drug used to treat hypercholesteremia. Such pluripotent effects of simvastatin 
complicates the mechanistic understanding of how adverse effects arise in the clinic; for 
example the association between lipophilic statin use and increased risk of glucose 
intolerance and diabetes (Cederberg et al., 2015; Sattar et al., 2010). 
Insulin secretion from the pancreatic beta-cell is promoted by glucose via oxidative 
metabolism (Maechler et al., 2010; Affourtit et al., 2018). The resultant increase in cytosolic 
ATP/ADP ratio blocks the activity of ATP-sensitive K+ channels (KATP) which leads to 
depolarization of the plasma-membrane potential (Vm) and activation of voltage-gated Ca2+ 
channels (VGCCs). Ca2+ influx through VGCCs promotes insulin secretion (Ashcroft et al., 
1994). In pancreatic β-cells mitochondrial respiration is shown to enhance L-type VGCC 
activity (Smith et al., 1989).  
Several “off targets” for simvastatin are recognised in β-cells. For example chronic 
simvastatin impairs mitochondrial respiration and ATP production (Zhou et al., 2014; Urbano 
et al., 2017). Such chronic effects are mediated by a decrease in activity of the mETC 
complexes (Urbano et al., 2017) with an associated  impairment in ATP production (Zhou et 
al., 2014; Urbano et al., 2017). Simvastatin likewise disrupts mETC (IC50 ~ 2 µM) in skeletal 
muscle to depolarize the inner mitochondrial membrane potential (ΔΨmit; Sirvent, Mercier, 
et al., 2005).  Consequently an impairment in mitochondrial function is expected to decrease 
VGCC activity and Ca2+ influx, events that will suppress insulin secretion. Indeed a similar 
mechanism has already been proposed to explain the decrease in artery vascular smooth 
muscle tone seen with statins (Almukhtar et al., 2016); a tissue in which VGCCs are also 
modulated by ATP and mitochondrial respiration (McHugh and Beech, 1996; Ohya and 
Sperelakis, 1989). 
The aims of the present study were to investigate these ideas and determine if simvastatin 
can adversely affect the activity of L-type Ca2+ channels in pancreatic β-cell indirectly via 
mitochondrial effects and in doing so reveal a novel outcome for the action of drugs for which 
mETC is an “off target”.  
 
Materials and methods 
Preparation of β-cells  
For this study murine beta-cells were used (Daunt et al., 2006). Primary pancreatic beta-
cells were dissociated from islets of male CD1 mice (30-35 g) as described (Smith et al., 
1999). Mice were stunned by cervical dislocation and killed by decapitation. Islets were 
extracted by collagenase digestion and single cells liberated by dissociation with trypsin-
EDTA. Cells were maintained in RPMI 1640 media, supplemented with 11 mM glucose, 10 
% FBS, 10 mM HEPES, 50 μg/ml penicillin and streptomycin. Cells were kept up to 2 days 
in a humidified atmosphere of 5% CO2/95% at 37 °C. All animal care and experimental 
procedures were carried out in accordance with the UK Home Office Animals (Scientific 
Procedures) Act (1986). To reduce and replace animal use, the murine beta-cell line MIN6 
(Daunt et al., 2006; Smith et al., 2001) were used for measurement of KATP  and L-type Ca2+ 
channel activity, Ca2+ imaging and beta-cell respiration. MIN6 cells, passage 35-40 were 
from our own stock and were sourced as originally described (Smith et al., 2001); these 
were maintained as for primary beta-cells but without antibiotics. The suitability of MIN6 cells 
as a model system in which to study mitochondrial function of beta-cells has already been 
argued (Elmorsy et al., 2017). 
Mitochondrial respiration 
The rate of oxygen consumption (OCR) was used to measure mitochondrial respiration in-
situ with Clark oxygen electrodes (Rank Brothers, Bottisham, UK) as previously described 
(Daunt et al., 2006). Known densities of MIN6 cells were incubated at 32oC in Hanks solution 
which contained (in mM): 137 NaCl, 5.6 KCl, 1.2 MgCl2, 2.6 CaCl2, 1.2 NaH2PO4, 4.2 
NaHCO3 10 HEPES (pH 7.4 with NaOH). For OCR cells were first incubated in the absence 
of substrate, basal, followed by stimulation with10 mM glucose for 10 minutes after which a 
single concentration of drug was tested. The OCR was corrected for background 
consumption of O2 by the electrode by subtraction of the OCR measured in 6 mM NaN3, a 
treatment which blocks oxidative respiration at mETC complex IV. The effect of drugs is 
expressed as the change in OCR relative to that stimulated by glucose in the same 
suspension. Only data from glucose-sensitive suspensions was used (>10% increase in 
response to 10 mM glucose).  
Imaging studies 
Changes in inner mitochondrial membrane potential (ΔΨmit) and cytosolic calcium 
concentration ([Ca2+]i) were monitored with rhodamine-123 (Rh123) and the calcium 
fluophore FLUO-4 respectively as previously described (Daunt et al., 2006; Duchen et al., 
1993). Cells were perifused in a modified Hanks solution at 32oC. Regions of interest (ROI) 
were drawn around cells, corrected for background fluorescence by subtraction, and the 
average fluorescence intensity calculated. To sample the total cell population, ROIs were 
from both single cells and cell clusters. For each experimental group, samples were pooled 
from multiple visual fields from at least 4 different cell preparations. Image analysis was 
performed with custom scripts written in Labtalk (OriginLab Corporation, MA USA). 
For ΔΨmit, images were captured at a frame rate of 1 Hz with a Photonics ISIS CCD camera, 
DT3155 frame grabber (Data Translation, UK) and Imaging workbench software (IW6 
INDEC BioSystems, Santa Clara, USA). Only ROIs that responded 1 µM FCCP (carbonyl 
cyanide-4-(trifluoromethoxy) phenylhydrazone), a mitochondrial protonophore which 
collapses ΔΨmit and results in a fluorescence increase, were chosen for further analysis 
(Duchen et al., 1993; Elmorsy et al., 2017). ROIs were normalised to the difference between 
the fluorescence measured in glucose (minimum fluorescence) and that in and that in the 
presence of 1 µM FCCP (maximum fluorescence) (Daunt et al., 2006). 
For [Ca2+]i images were captured at 1 Hz with a Coosnap HQ2 camera (Photometrics, UK) 
and Imaging workbench software. Only cells that responded to 10 mM glucose with an 
increase in steady-state [Ca2+]i greater than 10% compared to basal were chosen for further 
analysis. To calibrate [Ca2+]i, fluorescence changes were calibrated by a one-point method 
that involved permeabilization of the cells with saponin (0.01-0.1 % wt/v), with the maximum 
fluorescence value observed taken as Fmax. To calculate [Ca2+]i the following equation was 
used (Equation 1): 
 
[𝐶𝑎 2+] 𝑖 = 𝐾𝑑 ×
𝐹
𝐹𝑚𝑎𝑥 − 𝐹
 
Where F is the fluorescence (background subtracted), and Kd is the dissociation constant 
of Fluo-4: 345 nM. To quantify changes in [Ca2+]I, its mean (µ) and standard deviation  (σ) 
were calculated for the last 60 seconds of any given treatment, a period over which [Ca2+]I 
sustained a steady state. The variation in [Ca2+]I, as indicated by σ[Ca2+]I, was assumed to 
be indicative of underlying calcium-dependent action potential activity (Rorsman et al., 
1992). For statistical analysis µ[Ca2+]I and σ[Ca2+]I were normalised as percentage of that 
measured for glucose alone in the same ROI: Δµ[Ca2+]I and Δσ[Ca2+]I respectively. 
Measurement of L-type Ca2+ channel activity 
Measurement of L-type Ca2+ activity was performed with cell-attached patch-clamp, similar 
to that described (Smith et al., 1989). This method was used preferentially over whole-cell 
methods (Smith et al., 1989; Smith, 2009) to prevent K+ channel contamination. 
Patch pipettes were drawn from GC150TF capillary glass (Harvard Instruments), coated 
with Sylgard (Dow-Corning) and fire polished before use. Pipettes typically had resistances 
between 2-4 MΩ. The zero-current potential was adjusted with the pipette in the bath just 
before seal establishment. No corrections have been made for liquid junction potentials (<4 
mV). Currents were low pass filtered at 2 kHz (–3db, 8 pole Bessel), digitized at 10 kHz 
using pClamp 8.3 (Axon Instruments, Foster City, USA).  
To maximize channel detection, but minimize surface charge effects (Smith et al., 1993) the 
pipette contained (in mM): 0.1 µM BAY-K8644, 140 NaCl, BaCl2 10, HEPES 10 (pH 7.4 with 
NaOH). Cells were bathed in a high K+ Hanks solution which contained (in mM): 140 KCl, 
3.8 MgCl2, 1.2 NaH2PO4, 4.2 NaHCO3 10 HEPES (pH 7.4 with NaOH); a solution which 
electrochemically clamps Vm to  0mV.  
To record single Ca2+ channel activity, Vm was held at -90 mV and Ca2+ currents were 
elicited by pulses to -40 mV of 200 ms duration at 0.5 Hz. Leak and capacitance currents 
were removed by subtraction of the numerical average of records absent of activity. Channel 
activity, NPo, was recorded for 3-5 minutes, first in basal then after 10 minute incubation in 
10 mM glucose, followed by the addition of drug or vehicle.  
Single-channel data were analysed with custom scripts written in Labtalk using half-
amplitude threshold techniques as described (Smith et al., 1993). Drug effects on NPo were 
quantified as a percentage of its respective control values. Ca2+ currents are displayed 
conventionally as downward deflections.  
Assessment of intracellular ATP: Cell-attached KATP ion channel activity as a biosensor 
To monitor the acute intracellular ATP/ADP ratio, the activity of KATP channels in cell-
attached experiments was measured. This channel acts as a biosensor of the intracellular 
sub membrane ATP/ADP ratio and can be used to follow the energetic status of an  intact 
cell in real time (Gribble et al., 2000). For this, KATP channel activity was measured in cell-
attached experiments with a pipette potential, Vp, of 0 mV. The pipette contained (in mmol/l): 
140 KCl, CaCl2 2.6, MgCl2 1.2, HEPES 10 (pH 7.4 with NaOH). KATP currents were low pass 
filtered at 2 kHz (–3db, 8 pole Bessel) and digitized at 10 kHz using PClamp. Single-channel 
data were analysed with half-amplitude threshold techniques as implemented in Clampfit 
Ver. 10.6 (Axon Instruments, Foster City, USA). Channel activity, NPo, was measured 
continuously, in the absence then presence of 10 mM glucose followed by drug additions. 
An increase in NPo reflects a decrease in ATP/ADP (Gribble et al., 2000); a phenomenon 
expected to  occur with an impairment of glucose metabolism (Köhler et al., 1998; Kiranadi 
et al., 1991).  
 
Drugs 
Simvastatin and pravastatin were obtained from Tocris Bioscience, Bristol, UK. FCCP was 
obtained from Sigma-Aldrich, Poole, UK. Simvastatin was used in its lipophilic, lactone, form. 
Simvastatin, rotenone and FCCP were dissolved in ethanol or DMSO; Pravastatin was 
dissolved in H2O.  Drug additions were made from serially diluted stocks such that the 
vehicle was always applied at the same final concentration; for the electrophysiology this 
was 0.1% vol/vol and for the OCR this was 1% vol/vol. 
Statistical Analysis 
Statistical analysis was performed using either Graphpad PRISM version 7.03 (San Diego, 
California USA) or StatsDirect 3.1 (Cambridge, UK), data were tested with the D'Agostino & 
Pearson omnibus normality test and the appropriate statistical test used as given in the text. 
The concentration-response relationship for the block of OCR by simvastatin was quantified 
by fitting the data with the equation:   
Y    =   1/(1 + ( [S] / IC50 )h ) 
Where Y is the fractional OCR, relative to that measured under control conditions, h is the 
slope index, [S] is the free simvastatin concentration and IC50 the concentration that 
produces half-maximal inhibition. Since 0.1% BSA binds simvastatin to decrease its free 
concentration ~10 fold (Shi et al., 2017; Real et al., 2018), [S] was taken to be  1/10th of the 
added concentration. 
Data are quoted as either the mean  SEM or median with 5 to 95% confidence intervals 
(C.I.), where n is the number of separate determinations. Statistical significance is defined 
as P <0.05 and is flagged in graphics as *, ** (p<0.01) or *** (p<0.001). 
 
Results  
Simvastatin blocks oxidative respiration. 
In 5 mM glucose the Δψmit of primary mouse beta-cells was hyperpolarised, as revealed by 
a reversible increase in Rh123 fluorescence on removal of the sugar (Figs. 1A, 1E). Addition 
of 1 µM FCCP dissipated Δψmit and maximized Rh123 fluorescence (Duchen et al., 1993). 
The effects of glucose and FCCP on  Δψmit  were similar to those previously  described in 
both MIN6 and primary beta-cells (Duchen et al., 1993; Daunt et al., 2006; Elmorsy et al., 
2017; Smith et al., 1999). In the presence of glucose, 10 µM simvastatin depolarised Δψmit 
(Fig. 1B). This effect consisted of an initial transient increase in Rh123 fluorescence 
superimposed upon an upward trend sometimes with stepwise increases. In Fig 1B, 10 µM 
simvastatin only partially collapsed Δψmit, since Δψmit was dissipated on addition of 1 µM 
FCCP. Overall, 10 µM simvastatin depolarised Δψmit by ~90% relative to its DMSO vehicle 
control (Fig. 2A; Kruskal Wallis, Dunn’s multiple comparison test); neither 10 µM of the 
hydrophilic statin pravastatin (Figs. 1C, 2A) nor its solvent (0.1% vol/vol DMSO) affected 
Δψmit (Fig. 2A). At 3 µM, simvastatin produced variable but significant decreases in Δψmit, 
smaller in magnitude than that seen with 10 µM of the drug (Fig. 2A). Simvastatin at 1 µM 
failed to affect Δψmit, even after 75 minutes incubation, the longest period tested (Figs. 1D, 
2A). These data suggest that the IC50 for Δψmit depolarization by simvastatin lies between 1 
to 10 µM. At 1 µM, rotenone the positive control, depolarized Δψmit  (Fig 1E) like that seen 
with 3-10 µM simvastatin (Fig 2A; Kruskal Wallis, Dunn’s multiple comparison test).  
To further investigate the concentration effect of simvastatin on mitochondrial function, 
oxidative respiration, a direct measure of metabolic flux, was measured in the murine beta-
cell line MIN6 (Daunt et al., 2006). Glucose increased oxygen consumption rate (OCR) by 
200 ± 24 % (n = 51) a value similar to that previously reported  for this cell line (Elmorsy et 
al., 2017; Daunt et al., 2006). At a clinically relevant concentration of 10 nM (Björkhem-
Bergman et al., 2011), simvastatin did not affect OCR. However, at higher concentrations 
simvastatin blocked OCR with an IC50 of 3.1 µM (2.1 to 4.6 µM, 95% C.I.) and slope 
coefficient of -0.8 (-0.6 to -1.0, 95% C.I.; Fig 2B). At 1 µM, rotenone blocked OCR by ~70%, 
an amount greater than that of the highest concentration of simvastatin tested. (Fig 2B). 
 
Simvastatin inhibits glucose stimulated Ca2+ influx  
To determine if the inhibitory effect of simvastatin on mitochondrial respiration was manifest 
on Ca2+ influx, cytosolic Ca2+ was measured in MIN6 beta-cells. In the absence of glucose, 
basal [Ca2+]i was 78 nM (, 63 to 107, 95% C.I.; Fig 3A). After a delay of between 1 to 4 
minutes, 10 mM glucose produced an initial decrease in [Ca2+]I followed by a biphasic 
increase. The latter consisted of an initial peak in [Ca2+]I which then decayed to an elevated 
level of 120 nM (100 to 156, 95% C.I.; Fig 3A); a value 1.5 fold (1.4 to 1.7, 95% C.I.) greater 
than basal (p<0.0001, Wilcoxon signed rank test). The latter was associated with transitory 
spikes indicative of underlying Ca2+-dependent action potential activity (Rorsman et al., 
1992). In the presence of the sugar, 10 µM but not 1 µM simvastatin caused a significant 
decrease in both the average [Ca2+]I  (Fig. 3B; p<0.05, Students t-test) and its associated 
variance or spiking activity (Fig. 3C; p<0.01, Mann-Whitney test) relative to the DMSO 
vehicle control.  
 
Simvastatin reverses glucose-stimulation of L-type Ca2+ channel activity 
Since L-type Ca2+ channels in this cell type are regulated by mitochondrial respiration (Smith 
et al., 1989), and simvastatin inhibited mETC and oxidative respiration, the action of the 
drug on VGCCs in functionally intact cells was explicitly explored with the cell-attached 
patch-clamp technique (Smith et al., 1989). Figure 4 shows that membrane potential 
depolarization elicited single-channel activity in MIN6  beta-cells indicative of L-type voltage-
gated Ca2+ channels that are found in pancreatic beta-cells (Smith et al., 1993; Schulla et 
al., 2003): voltage-dependent activation, a single channel current amplitude of ~ 1 pA at -40 
mV and prolongation of open channel lifetimes by 0.1 µM BAY-K8644, a dihydropyridine L-
type Ca2+ channel agonist (Smith et al., 1989, 1993).  Perifusion of glucose significantly 
increased channel activity (NPo) to 210 ± 9 % of basal (p = 0.013, Wilcoxon signed rank test 
relative to control, n = 14; Figs. 4B & D); an increase similar in magnitude to that previously 
reported for this channel in primary beta-cells (Smith et al., 1989). Figure 4C shows that 
subsequent addition of 1 µM simvastatin reversed the effect of glucose and decreased NPo 
back down to its basal value (Fig 4D; p <0.0001, Kruskal Wallis Dunn’s multiple comparison 
test). In the absence of glucose 1 µM simvastatin failed to affect channel activity (Fig. 4D; 
One sample t-test). Similar results were also seen with 10 µM simvastatin: a reversal of the 
stimulatory effect of 10 mM glucose on channel activity but with no effect in the absence of 
the sugar (Fig. 4D); these data are indicative of an indirect, glucose-dependent effect of 
simvastatin on this channel type. This latter idea is supported by the observation that the 
degree of inhibition in NPo produced by 1 µM simvastatin was linearly correlated (R2 > 0.91; 
p<0.001, Pearson R) with the magnitude of increase in NPo stimulated by glucose (Fig. 4E). 
Figure 4D also shows that the ability of simvastatin to reverse the stimulatory effect of 
glucose on L-type Ca2+ channel activity was mimicked by 1 µM rotenone, an established 
inhibitor of mETC and mitochondrial respiration.  
 
Rotenone but not Simvastatin reactivate glucose-blocked KATP channel activity 
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To investigate if Δψmit  depolarization was associated with a decrease in intracellular ATP 
levels, the level of sub-membrane ATP was monitored indirectly by measurement of KATP 
channel activity in cell-attached patches  (Gribble et al., 2000; Köhler et al., 1998; Kiranadi 
et al., 1991). Figure 5 demonstrates the decrease in KATP channel activity associated with 
the rise in intracellular ATP/ADP that occurs with oxidative metabolism of glucose (Köhler 
et al., 1998; Kiranadi et al., 1991). Subsequent addition of 1 µM rotenone led to an increase 
in channel activity (Figs. 5F 5G), whereas 1 µM FCCP produced an even larger increase 
(Fig. 5g) to effectively reverse the inhibitory effect of glucose on KATP channel activity. 
Addition of 10 µM of simvastatin failed to mimic the ability of rotenone to reactivate KATP 
channels blocked by glucose, but instead produced further inhibition (Figs. 5c, 5G); an effect 
previously shown to be due to a direct block of the channel protein itself by this drug (Real 
et al., 2018). Antimycin at 1 µM, similarly activated KATP like FCCP. Channel identity was 
confirmed by its abolition with 200 µM tolbutamide; a specific sulphonylurea inhibitor of KATP 
channels. 
 
Discussion 
 
In the pancreatic beta-cell, the lipophilic lactone form of the statin, simvastatin at 
concentrations greater than 1 µM depolarised Δψmit, reversed the glucose activation of L-
type Ca2+ channels and inhibited glucose-stimulated Ca2+ influx. In contrast, 10 µM of the 
hydrophilic statin pravastatin neither affected Δψmit or Ca2+ channel activity. Since all the 
effects of simvastatin were mimicked by rotenone, which also decreased the intracellular 
ATP/ADP ratio, supports the idea that this statin mediates its toxic effect on VGCCs via 
inhibition of oxidative respiration and a decrease in intracellular ATP/ADP; not by a direct 
action on the ion channel itself 
Effect of simvastatin on mitochondrial membrane potential and respiration 
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We show that in pancreatic β-cells acutely applied simvastatin depolarizes Δψmit . In most 
cells tested 10 µM, simvastatin collapsed Δψmit, whereas at 3 µM it produced more variable 
affects, whilst at 1 µM it was without detectable effect. These results suggest that the IC50 
for the lipophilic statin effect on mitochondrial function lies between 1 to 10 µM; a range that 
encompasses the IC50 of 3 µM for OCR; a potency similar to that seen in skeletal muscle: 
IC50 ~2 µM (Sirvent, Mercier, et al., 2005). Although the IC50 value we report is extracellular 
in origin this is probably representative of the value experienced by the mETC since our 
MIN6 cell line do not possess p-glycoprotein that would affect cellular levels  of  lipophilic 
drugs  (Daunt et al., 2006), moreover simvastatin has been reported to block p-glycoprotein 
(Wang et al., 2001). Based on data from respiration studies on intact mitochondria, it is 
argued that Complex I is the primary target for simvastatin (Sirvent, Bordenave, et al., 2005); 
an idea support by the similarly of the effects of rotenone, a selective complex I inhibitor,   to 
simvastatin in the present study. The inability of hydrophilic pravastatin to affect 
mitochondrial function is consistent with that previously reported for murine beta-cells (Zhou 
et al., 2014) and porcine coronary artery (Almukhtar et al., 2016).  
The reason that the lipophilic statin simvastatin in its lactone form (logP 4.68) affects 
mitochondrial function, whereas a lipophobic statin such as pravastatin (logP 0.59)  does 
not, probably relates to their ability to penetrate the inner mitochondrial membrane and gain 
access to either an intramembrane binding sites on the complexes (Degli Esposti, 1998) or 
disrupt membrane protein–lipid interactions (Hwang et al., 2003). Indeed, the ability of 
certain drug classes to inhibit mETC in isolated mitochondria has already been related to 
their lipophilicity (logP values) (Durazo et al., 2011). Similar ideas are also proposed to 
explain the ability of lipophilic compounds to directly block KATP-channels in the plasma 
membrane  (Real et al., 2018; Hwang et al., 2003). The stepwise depolarizations in Δψmit 
that were occasionally observed with simvastatin may result from the random fusion of 
intracellular simvastatin aggregates; where lipophilic drugs can sometimes form intracellular 
aggregates on penetration into the cell, such has been observed with clofazimnine (logP 
7.5) (Baik and Rosania, 2011).   
Effect of simvastatin on L-type Ca2+ channel activity. 
L-type VGCCs are positively modulated by Mg2+ nucleotide complexes (O’Rourke et al., 
1992; Ohya and Sperelakis, 1989), such that changes in the cytosolic ATP/ADP ratio are 
expected to affect the activity of these ion channels. Indeed, both increases and decreases 
in the activity of L-type VGCCs in response to metabolic stimulation and mitochondrial 
inhibition respectively has already been described for both pancreatic beta-cells (Smith et 
al., 1989) and smooth muscle (McHugh and Beech, 1996). Our observations that glucose 
stimulated L-type VGCCs activity and that both simvastatin and rotenone reversed this 
effect, are consistent with this idea, where a depolarization in Δψmit , like that produced by 
simvastatin and rotenone, is known to decrease the cytosolic ATP/ADP ratio (Duchen et al., 
1993) and inhibit this channel. Indeed, we too demonstrate that rotenone can decrease the 
cytosolic ATP/ADP ratio as illustrated by its ability to activate KATP channels blocked by 
glucose like that observed for other chemical disruptors of mitochondrial function such as 
antimycin, FCCP and others (Köhler et al., 1998; Kiranadi et al., 1991). We presume that 
simvastatin also decreases the cytosolic ATP/ADP given it ability to inhibit OCR and 
depolarize Δψmit just like rotenone. However these effects of simvastatin were not 
associated with activation of the KATP channel since they were masked by the potent ability 
of simvastatin to directly interact with the ion channel protein and inhibit it as we have 
previously demonstrated (Real et al., 2018). 
Our data are consistent with whole-cell voltage-clamp studies on pancreatic beta-cells 
where simvastatin blocked L-type Ca2+ currents with an  IC50 of 2 µM (Yada et al., 1999), a 
value similar to what we found for oxidative respiration. Although, other lipophilic 
compounds, such as Triton X-100 (Narang et al., 2013) and barbiturates (Kozlowski and 
Ashford, 1991) can also block L-type Ca2+ channels they appear to do so via a direct, 
anaesthetic-like, mechanism. The fact that the inhibition of VGCC activity was glucose-
dependent and was mimicked by rotenone suggest that this block is mechanistically indirect 
and occurs via an inhibition of oxidative respiration and decreased metabolic regulation of 
this channel type. This idea is supported by the fact that simvastatin failed to affect the L-
type Ca2+ channel in the absence of glucose and only abolished the stimulatory effect of 
glucose. Indeed, one technical advantage of the cell-attached patch clamp method over 
other configurations is that the cell is maintained in an intact functional state. This means 
that mitochondrial metabolism and signalling pathways continue to modulate channel 
activity within the patch. 
We also demonstrate that the use of micromolar concentrations of simvastatin to study 
mitochondrial actions preclude any parallel investigation of changes in KATP-channel activity 
that may result from an alteration in cytosolic ATP due to the fact that this drug acts to 
directly block and silence this particular  ion channel species as we reported previously (Real 
et al., 2018).  
Effect of simvastatin on Ca2+ influx. 
The reduction in the [Ca2+]I variance we observed with 10 µM simvastatin is consistent with 
a decline in the Ca2+ dependent electrical activity that would result from a decrease in L-type 
Ca2+ channel activity (Rorsman et al., 1992). The observation that 1 µM simvastatin was 
effective in the patch-clamp studies but failed to affect intracellular Ca2+ levels may relate to 
the dissimilarity in temperatures employed:  22°C and 32°C respectively. Since oxidative 
respiration in these cells has a  Q10 of 5 (Ohta et al., 1990; Escolar et al., 1990) a greater 
concentration of simvastatin may be required to block the higher metabolic flux of glucose-
metabolism at 32°C. This reason may also contribute to the explanation of why, in a previous 
study (Real et al., 2018), we failed to see an effect of 1 µM simvastatin on glucose stimulated 
insulin secretion at 32°C. 
Physiological  Implications  
The concentrations of simvastatin that we found to acutely affect mitochondrial function and 
VGCC activity (1-10 µM) are similar to those used in other in-vitro studies (Ishikawa et al., 
2006; Zhou et al., 2014; Sirvent, Mercier, et al., 2005), but are in excess of those normally 
measured clinically (0.1-10 nM) (Björkhem-Bergman et al., 2011). It should be noted that  in 
many previous studies, the effects of simvastatin on pancreatic beta-cell function looked at  
long term effects after chronic incubation of many hour to days, whereas here we have 
investigated  acute  effects on the minute to minute time scale . Under certain circumstances, 
e.g. drug interactions,  plasma levels of simvastatin can reach ~1 µM (Lilja et al., 1998): a 
concentration sufficiently  high enough  to elicit mitochondrial dysfunction in pancreatic beta-
cells and perhaps contribute to the diabetogenic effect of this particular class of drug. The 
ability of simvastatin to impair beta-cell function arises from at least two mechanisms: via a 
direct block of KATP channels at nanomolar concentrations which is mitochondrial 
independent. Whereas at higher, micromolar, concentrations mitochondria respiration is 
impaired to decrease cytosolic ATP levels and inhibit metabolic regulation of L-type Ca2+ 
channels. In fact, the actual impact on insulin secretion will be the result of a convolution of 
these two process combined with other ATP-dependent process that will also be 
compromised such as exocytosis (Eliasson et al., 1996). 
In conclusion our data highlights the fact that the cellular toxicity of an agent, which can 
acutely target and impair mitochondrial function, may in part result from decreased L-type 
Ca2+ channel activity, Ca2+ influx and compromised cell functions that are Ca2+ dependent. 
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Fig. 1. Simvastatin depolarizes the inner mitochondrial membrane potential, Δψmit. 
Representative traces of Rh123 fluorescence for primary mouse β-cells recorded in 
response to conditions indicated. Arrows show the points where drugs were perifused. All in 
the presence of 5 mM glucose, unless otherwise indicated. Each record is the average of 
several cells viewed within a given field normalised as a percentage of their response to 1 
µM FCCP. A) Effect of glucose removal. B) Effect of 10 µM simvastatin, a lipophilic statin.  
C) Effect of 10 µM pravastatin, a lipophobic statin. D) Effect of 1 µM simvastatin. E) Effect 
of glucose removal and 1 µM rotenone.  
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Fig. 2. Simvastatin inhibits mitochondrial function in murine beta-cells. A) Effect of 0.1% 
vol/vol DMSO (n = 10), 10 µM pravastatin (Prav; n = 10), 1 µM simvastatin (Sim1; n = 5), 3 
µM simvastatin (Sim3, n = 14), 10 µM simvastatin (Sim10; n = 16) and 1 µM rotenone (Rot, 
n = 71) on Rh123 fluorescence as a percentage of that produced by 1 µM FCCP in primary 
mouse pancreatic beta-cells. Data are from 7 preparations and are shown as the median, 
inter-quartile and 10-90% values.  Statistical comparison by Kruskal Wallis with Dunn’s 
multiple comparison test. B) Simvastatin concentration-effect relationship for the block of 
glucose-stimulated oxygen consumption (OCR) in MIN6 beta-cells. Data, closed squares, 
are shown as mean ± S.E.M (n= 5-9). Solid line is drawn to equation 1 with values given in 
the text. The open square is the mean± S.E.M effect produced by 1 µM rotenone on glucose-
stimulated OCR (n= 11). 
 
 
  
Fig. 3. Glucose elicits calcium influx, which is inhibited by simvastatin. A) Representative 
intracellular calcium, [Ca2+]i, traces for five MIN6 beta-cells clusters all recorded in the same 
field in response to the conditions indicated. Additions are perifused from the indicative 
arrows. B-C) Effect of 1 µM simvastatin (Simv1; n = 42) and its control 0.1% vol/vol DMSO 
(DMSO1, n = 42), and 10 µM simvastatin (Simv10; n = 34) and its control, 1% vol/vol DMSO 
(DMSO10, n = 44), on mean [Ca2+]I (B) and its standard deviation (C) as a percentage of 
that measured in 10 mM glucose in the absence of drug or its vehicle. In all cases statistical 
tests are between simvastatin and its relevant DMSO control either Students t-test or Mann-
Whitney test.  Data are from 9 preparations and are shown as the median, inter-quartile and 
10-90% values. 
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Figure  4. Simvastatin reverses the metabolic stimulation of L-type calcium channel activity. 
A-C) Single Ca2+ channel activity recorded from the same cell-attached patched on a MIN6 
beta-cell. The pipette contained 10 mM Ba2+ and 0.1 µM BAY K  8644 to enhance resolution  
of single-channel currents. Currents were elicited by a step to -40 mV from a holding 
potential of -90 mV. Data filtered at 500 Hz. In each case the top four traces are consecutive 
records: A) Control conditions, B) after 5 minutes in 10 mM glucose, and then C) after 5 
minutes in 10 mM glucose and 1 µM simvastatin. Lowest trace in each panel is the ensemble 
average of 100 traces. Note the increase in channel activity seen with glucose (B) relative 
to control (A), and how this was increase was reversed by simvastatin (C) back to control 
values (A). D) Changes in channel activity (NPo) relative to respective basal for the 
conditions indicated: 1 µM simvastatin on basal (Sim1; n = 5), 10 µM simvastatin on basal 
(Sim10; n = 6), 10 mM glucose (Glu; n = 14), 10 mM glucose + 1 µM simvastatin (GSim1; n 
=14), 10 mM glucose + 10 µM simvastatin (GSim10; n = 7), 10 mM glucose + 1 µM Rotenone 
(GRot; n = 4). The effects of simvastatin and rotenone in the presence of glucose were 
statistically indistinguishable from each other (Kruskal Wallis Dunn’s multiple comparison 
test) E) Relationship between inhibition of channel activity produced by 1 µM simvastatin in 
the presence of 10 mM glucose (Sim1) and the degree of stimulation produced by the sugar. 
Solid line is a fit to the data by linear regression with a slope of 1.35 ± 0.09; dotted lines are 
the 95% confidence intervals of the fit 
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Figure  5. Effects of glucose and mitochondrial toxins on KATP channel.  A-C) KATP channel 
activity recorded from the same cell-attached patched on a MIN6 beta-cell: A) Control 
conditions, B) after 5 minutes in 10 mM glucose, and then C) after 5 minutes in 10 mM 
glucose and 10 µM simvastatin. Note further block in activity with simvastatin. D-F) KATP 
channel activity recorded from a different cell-attached patched: D) Control conditions, E) 
after 5 minutes in 10 mM glucose, and then F) after 5 minutes in 10 mM glucose and 1 µM 
rotenone. Rotenone clearly activates the KATP channel in F) whereas in C) simvastatin 
leads to a further block. G) Changes in channel activity (NPo) relative to glucose for the 
conditions indicated except Tolbutamide which is relative to FCCP: Absence of glucose 
(Basa; n = 58), DMSO (DMSO; n = 4), 10 µM simvastatin (Sim; n = 6), 1 µM Rotenone (Rot; 
n = 10) 1 µM Antimycin (Ant; n = 5 ), 100 nM FCCP (FCCP; n =25), 200 µM Tolbutamide 
(Tolb; n = 9). Statistical significance for the Sim, Rot, Ant and FCCP is with Kruskal -Wallis 
followed by an all pairwise post hoc test (Dwass-Steel-Chrichlow-Fligner). The effects of 
rotenone and antimycin in the presence of glucose were statistically indistinguishable from 
each other.  
